Abstract
4,6-diarylpyrimidones as constrained chalcone analogues have been synthesised in the present study. The synthesised compounds were evaluated against a panel of human cancer cell lines. Striking selectivity was displayed by the compounds against MiaPaCa (Pancreatic) cell lines while PC-3 (prostate) and A-549 (lung) cell lines were almost resistant to the exposure of the test compounds. Compound SK – 25 exhibited remarkable cytotoxicity against MiaPaca-2 cell line with an IC50 value of 1.95 µM and was found to induce apoptosis evidenced through phase contrast microscopy, DAPI staining and mitochondrial membrane potential loss. The cell phase distribution studies indicated that the apoptotic population increased from 1.79% in control sample to 30.33 % in sample treated with 20 µM compound SK-25.
Keywords: Apoptosis, cell cycle, chalcone, contrained, cytotoxic, pyrimidones.
Graphical Abstract
Anti-Cancer Agents in Medicinal Chemistry
Title:4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents
Volume: 15 Issue: 6
Author(s): Dinesh Kumar, Kunal Nepali, PMS Bedi, Suresh Kumar, Fayaz Malik and Subheet Jain
Affiliation:
Keywords: Apoptosis, cell cycle, chalcone, contrained, cytotoxic, pyrimidones.
Abstract: 4,6-diarylpyrimidones as constrained chalcone analogues have been synthesised in the present study. The synthesised compounds were evaluated against a panel of human cancer cell lines. Striking selectivity was displayed by the compounds against MiaPaCa (Pancreatic) cell lines while PC-3 (prostate) and A-549 (lung) cell lines were almost resistant to the exposure of the test compounds. Compound SK – 25 exhibited remarkable cytotoxicity against MiaPaca-2 cell line with an IC50 value of 1.95 µM and was found to induce apoptosis evidenced through phase contrast microscopy, DAPI staining and mitochondrial membrane potential loss. The cell phase distribution studies indicated that the apoptotic population increased from 1.79% in control sample to 30.33 % in sample treated with 20 µM compound SK-25.
Export Options
About this article
Cite this article as:
Kumar Dinesh, Nepali Kunal, Bedi PMS, Kumar Suresh, Malik Fayaz and Jain Subheet, 4,6-diaryl Pyrimidones as Constrained Chalcone Analogues: Design, Synthesis and Evaluation as Antiproliferative Agents, Anti-Cancer Agents in Medicinal Chemistry 2015; 15 (6) . https://dx.doi.org/10.2174/1871520615666150318101436
DOI https://dx.doi.org/10.2174/1871520615666150318101436 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Design, Synthesis and Screening Studies of Potent Thiazol-2-Amine Derivatives as Fibroblast Growth Factor Receptor 1 Inhibitors
Current Topics in Medicinal Chemistry Doxorubicin Sensitizes the Non-Small Cell Lung Cancer Cells to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Mediated (TRAIL) Apoptosis In Vitro but not In Vivo
Letters in Drug Design & Discovery Telomere Maintenance as Therapeutic Target in Embryonal Tumours
Anti-Cancer Agents in Medicinal Chemistry Future Oncotargets: Targeting Overexpressed Conserved Protein Targets in Androgen Independent Prostate Cancer Cell Lines
Anti-Cancer Agents in Medicinal Chemistry Elucidation of S-Allylcysteine Role in Inducing Apoptosis by Inhibiting PD-L1 Expression in Human Lung Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Improved 3D-QSAR Prediction by Multiple Conformational Alignments and Molecular Docking Studies to Design and Discover HIV-I Protease Inhibitors
Current HIV Research Recent Progress in Clinical Development of Therapeutic Antibodies Targeting Glycan-Binding Proteins
Current Drug Targets Cancer Therapeutics: Emerging Targets and Trends
Current Cancer Therapy Reviews Resveratrol and Its Analogues: Promising Antitumor Agents
Anti-Cancer Agents in Medicinal Chemistry Reversing Breast Cancer Stem Cell into Breast Somatic Stem Cell
Current Pharmaceutical Biotechnology Targeted Therapy in Colorectal Cancer: Current Status and Future Challenges
Current Medicinal Chemistry Pharmaceutical Perspectives of HECT-TYPE Ubiquitin Ligase Smurf1
Current Pharmaceutical Design <i>In Silico</i> Docking Studies of Vascular Endothelial Growth Factor-A (VEGFA): Possible Implications in Chronic Myeloid Leukemia (CML) Therapy
Current Proteomics Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect
Current Drug Targets MicroRNAs in Tumorigenesis
Current Pharmaceutical Biotechnology MicroRNA Therapeutics: The Emerging Anticancer Strategies
Recent Patents on Anti-Cancer Drug Discovery Bladder Cancer Chemopreventive Agents: Current Knowledge and Concepts
Mini-Reviews in Medicinal Chemistry Developments in Targeted Therapy of Advanced Gastrointestinal Stromal Tumors
Recent Patents on Anti-Cancer Drug Discovery Bisphosphonates: Molecular Mechanisms of Action and Effects on Bone Cells, Monocytes and Macrophages
Current Pharmaceutical Design New Frontiers in Cystic Fibrosis Therapy: The Case of Stem Cells
Clinical Immunology, Endocrine & Metabolic Drugs (Discontinued)